

U.S. POSTAL SERVICE
U.S. DEPARTMENT OF COMMERCE

Software for from 149,- DFL

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use all Party streets as necessary.)

Sheet 1 of 2

Application Number	10/647,358
Filing Date	August 25, 2003
First Named Inventor	Charles L. Bisgaier, et al.
Art Unit	1616
Examiner Name	John Pak
Attorney Docket Number	PC17370

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Case No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Page, Column, Line, Where Relevant Passages Or Relevant Figures Appear
		Country Code "Number" "Ind Code" (if known)			T*
		EP0401705A2 (Corresp to JP2003-20226)	12-12-1990	E. R. Squibb & Sons Inc	
		JP2002-508320A (Corresp to WO1999/30704)	03-19-2002	Warner-Lambert Company	
		JP03-20226A (Corresp to EP0401705)	01-29-1991	E. R. Squibb & Sons Inc	
		WO1996/30326A1	10-03-1996	Warner-Lambert Company	
		WO1997/38694A1	10-23-1997	Merck & Co Inc	
		WO1999/30704A1 (Corresp to JP2002-50832)	06-24-1999	Warner-Lambert Company	

EXAMINER: Initial if reference considered. Whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional)." See *Kinds Code of USPTO Patent Documents* at www.uspto.gov or MPEP 601.04. "Enter Office that issued the document, by the two-letter code (WPO = Standard ST.1). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document." "If of document by the appropriate symbols as indicated on the document under WPO Standard ST.18 if possible." "Applicant is to place a check mark here if English language

The collection of information is required by 37 CFR 1.97 and 1.98. The information is requested to obtain or retain a benefit for the public which is to be used (as by the USPTO) to process an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Box 1450, Ann Arbor, MI 48121-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: U.S. Patent and Trademark Office, P.O. Box 1450, Ann Arbor, MI 48121-1450.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(Use as many sheets as necessary)			
Sheet	2	of	2

Complete if Known

Application Number	10647,358
Filing Date	August 25, 2003
First Named Inventor	Charles L. Bisgaier, et al.
Art Unit	1618
Examiner Name	John Pak
Attorney Docket Number	PC17370

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AVIRAM, et al., "Interaction of Oxidized Low Density Lipoprotein with Macrophages In Atherosclerosis, and the Antithromboticity of Antioxidants", Eur J Clin Chem Clin Biochem, 1996, pp 599-608, Vol. 34	
		GRUNDY S. M., et al., "Atherogenic Dyslipidemia: Lipoprotein Abnormalities and Implications for Therapy", Amer J Cardiology, 1996, Vol. 75, pp 458-52B	
		HEINONEN T. M., et al., "Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol", J Cardio Pharm Therap, 1996, pp 117-122, Vol.1, No.2	
		ILLINGWORTH D. R., et al., "Comparative Effects of Lovastatin and Niacin in Primary Hypercholesterolemia, Arch Intern Med, 1994, pp 1588-1595, Vol.154, No.14	
		JONES P. H., et al., "Effect of gemfibrozil on level of lipoprotein (a) in Type II hyperlipoproteinemic subject, J Lipid Res, 1996, pp 1298-1308, Vol. 37	
		SHIOMI M., et al., "Suppression of established atherosclerosis and xanthomas in immature WHHL rabbits by keeping their serum cholesterol levels extremely low", Atherosclerosis, 1990, pp 69-80, Vol.83	
		STONE N. J., et al., "Lipid Management: Current Diet and Drug Treatment Options," Amer J Med, 1996, pp 4A40S-4A49S, Vol.101 (suppl 4A)	

Examiner Signature	Date Considered
	7/9/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.